Kyverna Therapeutics, Inc. (KYTX) vs REGENXBIO Inc. (RGNX)

A side-by-side comparison of Kyverna Therapeutics, Inc. and REGENXBIO Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — KYTX vs RGNX

growth of $100 · dividends reinvested · last 3y
KYTX -78.9% (-40.5%/yr)RGNX -52.4% (-21.9%/yr)RGNX compounded faster over this window
050100150Start $10020252026$21$48
KYTX RGNX

KYTX vs RGNX: by the numbers

  • •RGNX is the larger company ($390M vs $384M market cap).
  • •Both run net losses; KYTX's is the smaller (0.00% vs -112.58% net margin).

Metrics side by side

Valuation

MetricKYTXRGNX
P/S ratioN/A2.24
P/B ratio2.325.44

Profitability

MetricKYTXRGNX
Gross margin0.00%88.09%
Operating margin0.00%-94.08%
Net margin0.00%-112.58%
ROE-92.20%-273.72%
ROIC-80.67%-54.00%

Growth (annualized)

MetricKYTXRGNX
Revenue CAGR (5Y)N/A1.59%
Total return CAGR (5Y)N/A-24.15%

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.